Gastrointestinal Pharmacology

Correct Answer

C — Entecavir

Rationale

Entecavir is classified as a nucleoside analogue that inhibits HBV reverse transcriptase. Pegylated interferon alfa is an immunomodulatory agent. Bulevirtide is a hepatocyte entry inhibitor targeting the NTCP receptor. Sofosbuvir is an NS5B polymerase inhibitor used for hepatitis C.

Correct Answer

A — NS5B polymerase inhibitor — nucleoside analogue prodrug activated intracellularly to its triphosphate form, acting as a chain terminator of HCV RNA synthesis

Rationale

Sofosbuvir targets the NS5B protein — the HCV RNA-dependent RNA polymerase responsible for viral genome replication. It is administered as a prodrug and undergoes intracellular phosphorylation to its active uridine triphosphate analogue, which is then incorporated into the growing RNA chain by NS5B. The incorporated analogue lacks the 3'-hydroxyl group required for further elongation, terminating RNA synthesis. The three drug classes in HCV direct-acting antiviral therapy are distinguished by suffix conventions: NS3/4A protease inhibitors end in "-previr" (glecaprevir, voxilaprevir, grazoprevir); NS5A inhibitors end in "-asvir" (ledipasvir, velpatasvir, pibrentasvir); sofosbuvir is the prototypical NS5B inhibitor. HCV is an RNA virus and does not use reverse transcriptase (option D).

Correct Answer

D — NS3/4A protease inhibitor

Rationale

Glecaprevir is classified as an NS3/4A protease inhibitor. Sofosbuvir is an NS5B polymerase inhibitor. Pibrentasvir (glecaprevir's partner in the combination regimen) is an NS5A inhibitor. Entecavir and tenofovir are nucleoside/nucleotide analogues used for hepatitis B, not hepatitis C.

Correct Answer

B — Glutathione precursor and mucolytic agent

Rationale

N-acetylcysteine is classified as a glutathione precursor and mucolytic agent. It is not a CYP2E1 inhibitor, a hepatocyte growth factor receptor agonist, or a direct NAPQI scavenger — these represent common misconceptions about its mechanism.

Correct Answer

C — Tenofovir alafenamide

Rationale

Tenofovir alafenamide is classified as a nucleotide analogue prodrug with targeted hepatic activation, achieving high intrahepatic concentrations at doses that produce substantially lower plasma tenofovir exposure than tenofovir disoproxil fumarate. Entecavir is a nucleoside analogue. Tenofovir disoproxil fumarate is the predecessor prodrug associated with higher plasma tenofovir levels. Lamivudine is a nucleoside analogue with a low resistance barrier.

Correct Answer

A — Hepatocyte entry inhibitor targeting the sodium-taurocholate cotransporting polypeptide receptor

Rationale

Bulevirtide is classified as a hepatocyte entry inhibitor that blocks the NTCP receptor used by both HDV and HBV to enter hepatocytes. It is the first approved drug specifically for hepatitis D. The remaining options describe mechanisms not applicable to bulevirtide.

Correct Answer

D — Resistance to entecavir requires three concurrent mutations in the reverse transcriptase gene — individually insufficient to confer resistance — making simultaneous occurrence extremely rare in treatment-naive patients

Rationale

The barrier to resistance for a nucleoside analogue is determined by how many mutations the virus must accumulate to escape drug binding while retaining replication competence. Lamivudine resistance requires a single YMDD domain mutation (most commonly M204V/I), which develops in approximately 20 percent of patients per year — explaining why lamivudine is no longer recommended as first-line therapy. Entecavir resistance in treatment-naive patients requires three concurrent mutations in the reverse transcriptase gene; the probability of all three occurring simultaneously is extremely low, resulting in clinical resistance rates below 1 percent after 5 years in naive patients. In lamivudine-experienced patients, however, the pre-existing YMDD mutations constitute the first step toward entecavir resistance, dramatically lowering the additional mutational requirement. This is why tenofovir — which has no documented resistance in clinical practice — is preferred over entecavir in lamivudine-experienced patients.

Correct Answer

B — Pegylated interferon's immunomodulatory activity can precipitate acute-on-chronic liver failure in decompensated patients by amplifying the hepatic inflammatory response in a liver with marginal functional reserve

Rationale

Pegylated interferon exerts antiviral activity not only through direct antiviral effects but also through potent immunomodulation — stimulating innate and adaptive immune responses against HBV-infected hepatocytes. In compensated cirrhosis patients with adequate functional reserve, this immune activation can clear infected hepatocytes while the liver retains sufficient synthetic and metabolic capacity. In decompensated cirrhosis, the liver has already lost critical functional reserve (evidenced by coagulopathy, hypoalbuminemia, jaundice, encephalopathy, or ascites). Interferon-mediated immune activation amplifies hepatic inflammation in this already-marginal organ, overwhelming residual hepatocyte mass and precipitating acute-on-chronic liver failure — a potentially fatal syndrome. Nucleos(t)ide analogues, which work by blocking viral replication without immune stimulation, do not carry this risk and can be used safely in decompensated cirrhosis.

Correct Answer

A — Co-administration of amiodarone with sofosbuvir has caused serious and fatal bradycardia including complete heart block through an incompletely understood cardiac conduction mechanism

Rationale

The amiodarone-sofosbuvir interaction is one of the most clinically important drug interactions in hepatitis C therapy. Post-marketing case reports — including fatalities — of symptomatic bradycardia, sinus arrest, and complete heart block emerged when patients receiving amiodarone (or who had stopped amiodarone within the preceding months, given amiodarone's extremely long half-life of weeks to months) started sofosbuvir-containing regimens. The precise mechanism is not fully characterized but appears to involve additive or synergistic effects on cardiac conduction, possibly at the level of cardiac calcium channels or sinoatrial node automaticity. The FDA issued a safety communication classifying this as an absolute contraindication. Before starting any sofosbuvir-containing regimen, the medication list must be screened for amiodarone, and the drug's long half-life means patients who discontinued amiodarone recently may still carry significant tissue drug levels.

Correct Answer

C — Ledipasvir requires an acidic gastric environment for adequate dissolution and absorption; proton pump inhibitor-induced acid suppression significantly reduces ledipasvir bioavailability

Rationale

Ledipasvir is a weakly basic compound whose dissolution and absorption depend on an acidic gastric environment. Proton pump inhibitors raise intragastric pH substantially, reducing ledipasvir solubility in the stomach and impairing its absorption. Pharmacokinetic studies confirm that high-dose PPIs reduce ledipasvir exposure by approximately 60 to 70 percent. In patients on ledipasvir-containing regimens, PPIs should be avoided if possible; if acid suppression is essential, the PPI should be used at the lowest effective dose and taken simultaneously with the ledipasvir/sofosbuvir (not at other times of day), as this timing minimizes the pH-elevation window during drug absorption. This interaction does not apply to other DAA combinations that do not contain ledipasvir.

Correct Answer

D — Rifampin is a potent CYP3A4 and P-glycoprotein inducer that substantially reduces plasma concentrations of NS3/4A protease inhibitor components and sofosbuvir, risking treatment failure

Rationale

Rifampin is the most potent inducer of CYP3A4 and P-glycoprotein in clinical use. NS3/4A protease inhibitors are CYP3A4 and P-glycoprotein substrates; induction of these pathways markedly accelerates their metabolism and efflux, reducing plasma drug concentrations below therapeutic levels and risking treatment failure. Sofosbuvir is also a P-glycoprotein substrate; P-glycoprotein induction reduces sofosbuvir intestinal absorption. The practical consequence is that HCV direct-acting antiviral therapy must not be initiated while rifampin is being taken. The correct sequencing is to complete the rifampin course first and then initiate DAA therapy, or to switch rifampin to an alternative anti-tuberculosis regimen (such as rifabutin, a weaker inducer) that does not compromise DAA exposure. This is an explicit contraindication listed in DAA prescribing information.

Correct Answer

B — NS3/4A protease inhibitors are hepatically metabolized by CYP3A4; decompensated cirrhosis severely impairs this metabolism, causing drug accumulation that worsens hepatic function

Rationale

NS3/4A protease inhibitors (the "-previr" agents) are metabolized primarily by CYP3A4 in the liver. Decompensated cirrhosis (Child-Pugh class B or C) dramatically reduces hepatic metabolic capacity, including CYP3A4 activity. When protease inhibitors cannot be adequately metabolized, plasma and hepatic drug concentrations rise markedly, worsening hepatic function and potentially precipitating further decompensation. Clinical trials excluded decompensated patients from protease inhibitor regimens, and case reports of hepatic decompensation with these agents in cirrhotic patients have been documented. The preferred DAA regimen for patients with decompensated cirrhosis is sofosbuvir plus velpatasvir — an NS5B inhibitor plus NS5A inhibitor combination that does not include a protease inhibitor and can be used safely in this population.

Correct Answer

C — After 8 to 10 hours, NAPQI has already formed covalent adducts with hepatocyte proteins causing irreversible structural damage; replenishing glutathione at this stage cannot reverse established hepatocyte injury

Rationale

N-acetylcysteine works by replenishing glutathione, which then conjugates NAPQI to a non-toxic mercapturic acid derivative for excretion. This mechanism is prophylactic in character — it must work before NAPQI binds hepatocyte proteins. When glutathione stores are exhausted and NAPQI accumulates, it forms covalent adducts with cysteine residues on mitochondrial and cytosolic proteins, causing mitochondrial dysfunction, oxidative stress, and ultimately necrotic cell death. These covalent protein adducts are irreversible — no amount of subsequently replenished glutathione can displace NAPQI from already-bound proteins or restore function to already-damaged mitochondria. Early administration (within 8 hours) intercepts NAPQI before significant protein binding occurs; late administration can still provide some benefit by protecting surviving hepatocytes from ongoing NAPQI production but cannot undo established injury.

Correct Answer

A — Nucleos(t)ide analogues suppress HBV DNA replication but do not eliminate covalently closed circular DNA in hepatocyte nuclei, which serves as a persistent transcriptional template for viral protein production including surface antigen

Rationale

HBV establishes a stable nuclear reservoir of covalently closed circular DNA (cccDNA) in infected hepatocyte nuclei. cccDNA functions as a minichromosome that is transcribed by host RNA polymerase II to produce all viral RNAs — including pregenomic RNA (the template for reverse transcription) and subgenomic RNAs encoding surface antigen. Nucleos(t)ide analogues act downstream of cccDNA: they block the reverse transcriptase from converting pregenomic RNA into new HBV DNA, suppressing viral replication. However, they have no direct effect on the cccDNA template already present in the nucleus — cccDNA persists in infected hepatocytes and continues to drive transcription of HBV surface antigen. As long as cccDNA persists, surface antigen continues to be produced, preventing functional cure. Novel curative strategies targeting cccDNA directly (epigenetic silencing, RNA interference, capsid assembly modulators) are currently in clinical development.

Correct Answer

D — Tenofovir alafenamide — it achieves high intrahepatic concentrations at a low plasma dose, substantially reducing nephrotoxicity and bone density loss compared with tenofovir disoproxil fumarate

Rationale

This patient has significant renal impairment (eGFR 24), which directly influences agent selection among the preferred first-line HBV nucleos(t)ide analogues. Tenofovir disoproxil fumarate (TDF) causes nephrotoxicity through proximal tubular injury from high plasma tenofovir concentrations; it is problematic in patients with pre-existing CKD where further renal compromise is clinically important. Tenofovir alafenamide (TAF) delivers equivalent antiviral activity at a 25 mg dose that produces approximately 90 percent lower plasma tenofovir concentrations than TDF's 300 mg dose; intrahepatic drug concentrations are preserved through a more efficient prodrug activation mechanism. This pharmacokinetic profile translates into substantially less nephrotoxicity and less bone mineral density loss. TAF is the guideline-preferred agent in patients with renal impairment. Lamivudine (option C) has an unacceptably high resistance rate and is no longer recommended as first-line for any HBV patient.

Correct Answer

B — Do not start sofosbuvir-containing therapy while the patient is on amiodarone; coordinate with cardiology to evaluate whether amiodarone can be safely substituted before initiating HCV treatment

Rationale

Amiodarone combined with sofosbuvir is an absolute contraindication — not a dose-adjustable interaction or a monitorable risk — based on post-marketing case reports of serious and fatal bradycardia including complete heart block. The contraindication cannot be managed by dose reduction, cardiac monitoring, or substituting only the NS5A inhibitor component; sofosbuvir itself is the interacting partner. The correct approach is to address the amiodarone before starting HCV treatment. The cardiologist should evaluate whether the patient's atrial fibrillation can be managed with an alternative antiarrhythmic or rate-control agent (such as a beta-blocker or diltiazem) that does not carry this interaction. Importantly, amiodarone's extremely long half-life — weeks to months — means that even patients who have recently discontinued amiodarone may retain sufficient tissue levels to cause this interaction; a washout period of several months may be needed before sofosbuvir is safe.

Correct Answer

A — Although liver injury has not yet developed, NAPQI is still accumulating and glutathione stores are being depleted; N-acetylcysteine replenishes cysteine for glutathione synthesis now, before irreversible protein adduct formation is complete

Rationale

Normal liver function tests at 6 hours after overdose do not indicate safety — they indicate that hepatocyte destruction has not yet become extensive enough to release measurable transaminase quantities. Acetaminophen-induced liver injury characteristically peaks at 72 to 96 hours post-ingestion. At 6 hours, NAPQI production is actively ongoing as remaining acetaminophen continues to be metabolized by CYP2E1, and glutathione stores may already be substantially depleted. The therapeutic window for N-acetylcysteine is precisely this pre-injury phase: by replenishing cysteine and enabling ongoing glutathione synthesis, N-acetylcysteine intercepts NAPQI before enough protein adducts have formed to cause clinically significant hepatocyte death. Waiting for elevated transaminases to confirm injury before treating is the error that leads to acute liver failure in preventable cases. Immediate N-acetylcysteine is the standard of care when the Rumack-Matthew nomogram indicates high risk, regardless of initial liver function test results.

Correct Answer

C — Sofosbuvir/velpatasvir for 12 weeks — pan-genotypic coverage addresses genotype 3, and compensated cirrhosis typically warrants extended duration beyond the standard 8-week course

Rationale

Two clinical factors drive treatment selection and duration in this patient. First, genotype: genotype 3 is the most difficult HCV genotype to treat and requires a pan-genotypic regimen with demonstrated genotype 3 efficacy. Sofosbuvir/velpatasvir is pan-genotypic and covers genotype 3 effectively. Ledipasvir/sofosbuvir (option D) has limited genotype 3 efficacy and would be an inappropriate choice. Glecaprevir/pibrentasvir is also pan-genotypic but is a protease inhibitor-containing regimen; while it can be used in compensated cirrhosis, sofosbuvir/velpatasvir is commonly preferred. Second, cirrhosis: treatment-naive patients without cirrhosis can complete sofosbuvir/velpatasvir in 8 weeks. Compensated cirrhosis is generally an indication to extend to 12 weeks to maximize SVR rates, as patients with cirrhosis have higher viral burden and more complex disease. Decompensated cirrhosis (Child-Pugh B or C) requires protease inhibitor avoidance — this patient is Child-Pugh A and can receive standard DAA regimens.